SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tesaro, Inc. - TSRO

NEW YORK, Jan. 16, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Tesaro, Inc. ("Tesaro" or the "Company") (NASDAQ: TSRO).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Tesaro and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here to join a class action]

On January 12, 2018, Tesaro announced that it had updated the U.S. labeling for Varubi (rolapitant), indicated for the prevention of delayed nausea and vomiting associated with chemotherapy, after receiving reports of "[a]naphylaxis, anaphylactic shock and other serious hypersensitivity reactions . . . in the postmarketing setting, some requiring hospitalization."  The Company further stated that it "has issued a Dear Healthcare Professional (DHCP) letter."  On this news, Tesaro's share price has fallen sharply during intraday trading on January 16, 2018.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com

View original content:http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-tesaro-inc--tsro-300583260.html

SOURCE Pomerantz LLP